Clinical outcomes from a nationwide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow-up. results from the danbio registry

B Glintborg; IJ Sørensen; AG Loft; J Esbesen; H Lindegaard; DV Jensen; K Danebod; S Dieperink; O Hendricks; IMJ Hansen; A Linauskas; S Kristensen; LS Andersen; M Hossein; H Nordin; BL Andersen; S Chrysidis; JL Raun; N Manilo; J Grydehøj; EB Dalgaard; DD Pedersen; NS Krogh; ML Hetland

doi:10.1136/annrheumdis-2017-eular.1703

Clinical outcomes from a nationwide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow-up. results from the danbio registry

B Glintborg, IJ Sørensen, AG Loft, J Esbesen, H Lindegaard, DV Jensen, K Danebod, S Dieperink, O Hendricks, IMJ Hansen, A Linauskas, S Kristensen, LS Andersen, M Hossein, H Nordin, BL Andersen, S Chrysidis, JL Raun, N Manilo, J GrydehøjEB Dalgaard, DD Pedersen, NS Krogh, ML Hetland

Institut for Klinisk Medicin

Originalsprog	Engelsk
Artikelnummer	FRI0190
Tidsskrift	Annals of the Rheumatic Diseases
Vol/bind	76
Udgave nummer	Suppl 2
Sider (fra-til)	553-554
ISSN	0003-4967
DOI	https://doi.org/10.1136/annrheumdis-2017-eular.1703
Status	Udgivet - 2017

Adgang til dokumentet

10.1136/annrheumdis-2017-eular.1703

553.2.full.pdfForlagets udgivne version, 282 KB

https://ard.bmj.com/content/annrheumdis/76/Suppl_2/553.2.full.pdf

Citationsformater

Glintborg, B., Sørensen, IJ., Loft, AG., Esbesen, J., Lindegaard, H., Jensen, DV., Danebod, K., Dieperink, S., Hendricks, O., Hansen, IMJ., Linauskas, A., Kristensen, S., Andersen, LS., Hossein, M., Nordin, H., Andersen, BL., Chrysidis, S., Raun, JL., Manilo, N., ... Hetland, ML. (2017). Clinical outcomes from a nationwide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow-up. results from the danbio registry. Annals of the Rheumatic Diseases, 76(Suppl 2), 553-554. [FRI0190 ]. https://doi.org/10.1136/annrheumdis-2017-eular.1703

Clinical outcomes from a nationwide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow-up. results from the danbio registry. / Glintborg, B; Sørensen, IJ; Loft, AG et al.

I: Annals of the Rheumatic Diseases, Bind 76, Nr. Suppl 2, FRI0190 , 2017, s. 553-554.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Glintborg, B, Sørensen, IJ, Loft, AG, Esbesen, J, Lindegaard, H, Jensen, DV, Danebod, K, Dieperink, S, Hendricks, O, Hansen, IMJ, Linauskas, A, Kristensen, S, Andersen, LS, Hossein, M, Nordin, H, Andersen, BL, Chrysidis, S, Raun, JL, Manilo, N, Grydehøj, J, Dalgaard, EB, Pedersen, DD, Krogh, NS & Hetland, ML 2017, 'Clinical outcomes from a nationwide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow-up. results from the danbio registry', Annals of the Rheumatic Diseases, bind 76, nr. Suppl 2, FRI0190 , s. 553-554. https://doi.org/10.1136/annrheumdis-2017-eular.1703

Glintborg B, Sørensen IJ, Loft AG, Esbesen J, Lindegaard H, Jensen DV et al. Clinical outcomes from a nationwide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow-up. results from the danbio registry. Annals of the Rheumatic Diseases. 2017;76(Suppl 2):553-554. FRI0190 . doi: 10.1136/annrheumdis-2017-eular.1703

@article{eaf98df72a074a8ab906dd49e58b23b9,

title = "Clinical outcomes from a nationwide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow-up. results from the danbio registry",

author = "B Glintborg and IJ S{\o}rensen and AG Loft and J Esbesen and H Lindegaard and DV Jensen and K Danebod and S Dieperink and O Hendricks and IMJ Hansen and A Linauskas and S Kristensen and LS Andersen and M Hossein and H Nordin and BL Andersen and S Chrysidis and JL Raun and N Manilo and J Grydeh{\o}j and EB Dalgaard and DD Pedersen and NS Krogh and ML Hetland",

year = "2017",

doi = "10.1136/annrheumdis-2017-eular.1703",

language = "English",

volume = "76",

pages = "553--554",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "B M J Group",

number = "Suppl 2",

}

TY - ABST

T1 - Clinical outcomes from a nationwide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow-up. results from the danbio registry

AU - Glintborg, B

AU - Sørensen, IJ

AU - Loft, AG

AU - Esbesen, J

AU - Lindegaard, H

AU - Jensen, DV

AU - Danebod, K

AU - Dieperink, S

AU - Hendricks, O

AU - Hansen, IMJ

AU - Linauskas, A

AU - Kristensen, S

AU - Andersen, LS

AU - Hossein, M

AU - Nordin, H

AU - Andersen, BL

AU - Chrysidis, S

AU - Raun, JL

AU - Manilo, N

AU - Grydehøj, J

AU - Dalgaard, EB

AU - Pedersen, DD

AU - Krogh, NS

AU - Hetland, ML

PY - 2017

Y1 - 2017

U2 - 10.1136/annrheumdis-2017-eular.1703

DO - 10.1136/annrheumdis-2017-eular.1703

M3 - Conference abstract in journal

SN - 0003-4967

VL - 76

SP - 553

EP - 554

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - Suppl 2

M1 - FRI0190

ER -